A Phase 1, Randomized, Double-blind, Placebo-controlled, Parallel Group, Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of CT-P63 in Healthy Subjects
Latest Information Update: 06 Feb 2023
At a glance
- Drugs CT-P63 (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions
- Sponsors Celltrion
Most Recent Events
- 09 Aug 2022 Status changed from not yet recruiting to completed.
- 27 Aug 2021 New trial record